🇺🇸 FDA
Pipeline program

PD-L1/IDO Peptide Vaccine

UCDCC#290

Phase 1 mab active

Quick answer

PD-L1/IDO Peptide Vaccine for High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma is a Phase 1 program (mab) at IO Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
IO Biotech
Indication
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials